Markets:

Overview

News

Currencies

International

Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

3.230 +0.020 (+0.62%)

Streaming Delayed Price Updated: 10:02 AM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

October 12, 2022

From Agenus Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 10, 2022

Gainers Reshape Lifesciences (NASDAQ:RSLS) shares increased by 12.7% to $0.34 during Monday's after-market session. The market value of their outstanding shares is at $1.2 million.

Via Benzinga

Tilray Brands, Canopy Growth, Cronos Group And Other Big Gainers From Thursday ↗

October 07, 2022

U.S. stocks closed lower with the Dow Jones dropping more than 300 points on Thursday. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Agenus Stock Rose 18.4% on Thursday ↗

October 06, 2022

The company's shares climbed with help from insider buying.

Via The Motley Fool

Short Volatility Alert: Agenus Inc. ↗

August 31, 2022

On Tuesday, shares of Agenus Inc. (NASDAQ: AGEN) experienced volatile short activity. After the activity, the stock price went down 0.00% to $2.66. The overall sentiment for AGEN has been Neutral.

Via Benzinga

Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday ↗

October 07, 2022

Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday.

Via Benzinga

Agenus to Host “The Road Taken” R&D Event on November 12, 2022

October 05, 2022

From Agenus Inc.

Via GlobeNewswire

Recap: Agenus Q2 Earnings ↗

August 09, 2022

Agenus (NASDAQ:AGEN) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Agenus Q1 Earnings ↗

May 10, 2022

Agenus (NASDAQ:AGEN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

October 06, 2022

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of...

Via Benzinga

Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

October 05, 2022

From Agenus Inc.

Via GlobeNewswire

Recap: Agenus Q4 Earnings ↗

March 01, 2022

Agenus (NASDAQ:AGEN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Agenus...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

7 Penny Stocks That Actually Have a Buy Rating ↗

September 19, 2022

Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now.

Via InvestorPlace

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗

September 12, 2022

Via Benzinga

Agenus Begins Mid-Stage Global Studies On Colorectal And Skin Cancer Candidate ↗

September 12, 2022

Agenus (NASDAQ: AGEN) has initiated Phase 2 ACTIVATE trials of botensilimab to advance globally in metastatic patients who have progressed on available therapies. This global Phase 2 program include...

Via Benzinga

Agenus Earnings Perspective: Return On Capital Employed ↗

September 01, 2022

According to Benzinga Pro data, during Q2, Agenus (NASDAQ:AGEN) posted sales of $20.93 million. Earnings were up 2.71%, but Agenus still reported an overall loss of $49.23 million.

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

Agenus Commences Initial-Stage Advanced Tumors Study ↗

August 01, 2022

Agenus (NASDAQ: AGEN) has dosed the first patient in the Phase 1 clinical study of AGEN1571 in advanced solid tumors. AGEN1571is a novel anti-ILT2 antibody designed to modulate tumor-associated...

Via Benzinga

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report

July 27, 2022

Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET

From Agenus Inc.

Via GlobeNewswire

U.S. Stocks Turn Negative; 2U Shares Spike Higher ↗

June 29, 2022

U.S. stocks pared gains midway through trading, with all the three major indices turning lower on Wednesday.

Via Benzinga

Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday ↗

July 06, 2022

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.

Via Benzinga

Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session ↗

June 29, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its previously announced at-the-market offering.

Via Benzinga

This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday ↗

June 30, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.

Via Benzinga

Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer ↗

June 29, 2022

Via Benzinga

Agenus's Return On Capital Employed Insights ↗

June 08, 2022

According to Benzinga Pro data, during Q1, Agenus (NASDAQ:AGEN) posted sales of $25.94 million. Earnings were up 25.15%, but Agenus still reported an overall loss of $50.60 million.

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Looking Into Agenus's Return On Capital Employed ↗

March 03, 2022

Benzinga Pro data, Agenus (NASDAQ:AGEN) reported Q4 sales of $20.26 million. Earnings fell to a loss of $67.61 million, resulting in a 138.14% decrease from last quarter. Agenus...

Via Benzinga

41 Stocks Moving In Wednesday's Mid-Day Session ↗

March 02, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported...

Via Benzinga

68 Biggest Movers From Yesterday ↗

March 03, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Agenus Inc. - Common Stock (NQ:AGEN)

All News about Agenus Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today